Quality & complianceOfficial

Denmark flags supply problems for Fresenius Kabi ceftazidime 2000 mg injection

🇩🇰 DKMA · Mon 16 Nov 2026

The Danish Medicines Agency says Ceftazidim "Fresenius Kabi" 2000 mg is affected from mid-November 2026, with no end date given and commercial reasons cited.

The Danish Medicines Agency (DKMA) has published a supply notice for Ceftazidim "Fresenius Kabi" 2000 mg powder for solution for injection or infusion, saying there are current problems with availability. The product is supplied by Fresenius Kabi AB.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.